Synch has successfully advised the state-owned company Apotek Produktion & Laboratorier AB (APL) in connection with its contemplated acquisition of a manufacturing facility from Meribel Pharma Solutions. The facility specializes in the production of penicillins and currently employs approximately 80 people.
APL plays an important role in the public healthcare sector and is tasked with ensuring the preparedness and supply of medicines in times of crisis or war. The acquisition will provide APL with the technical capability to manufacture penicillins and will strengthen Sweden’s long-term production capacity for these essential medicines.
This important transaction brings both long-term security to domestic manufacturing capabilities of penicillin’s and at the same strengthen APL's CDMO offering. We look forward developing the Strängnäs facility to its full potential over the coming years! Our long collaboration with Synch and their deep understanding of APLs unique business model was crucial to keep up the speed throughout the transaction, comments Filip Ringborg VP Business Development.
The acquisition is subject to governmental approvals which are anticipated to be received within short. The transaction is expected to be completed during the third quarter of 2025.
Synch acted as legal advisor to APL with a team led by partner Andreas Börjesson, senior associate Sofia Tångelin and associate Therése Gardström, mainly assisted by partner Sara Sparring (commercial), senior associate Marcus Appeltofft (IT), and associates Amila Briga (corporate), Lina Persson (employment), Kristin Tell (commercial) and Clara Löfgren (FDI).
KPMG acted as financial advisor.
